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During the last 20 years various at tempts have been made at obta- 
ining reliable tests of autonomic reactivity in mentally ill individuals. 
Mostly epinephrine and methacholine have been used to induce blood 
pressure changes, the degree and patterns of which have been claimed to 
differentiate diagnostic and prognostic categories (MY~aSO~ et al.; 
LINDE~dA:NN and FI~CESlNGER; FUNKENSTEIN et al. 1950). However, 
FUNXENSTEI~r found the epinephrine test in itself to be without predic- 
tive value for the outcome of t reatment  (FuNKENSTEIN et al. 1952). 
Other authors have more and more tended to conclude that  the metha- 
choline test is only vaguely associated with prognostic factors (SLoANE 
et al. and LUNDE et al.), and lately most authors have completely failed 
to find any prognostic value in the test procedures (HoFFE~ and CAI, L- 
BECK 1959a; SATTE~FIELD; OZTUX~K et al. ; BRAIYN and RETTEK; BRILL 
et al.). 
Atropine is another drug which has been used to differentiate groups 
of mentally ill patients. HOrFE~ (1954, 1959b) found that  schizophrenic 
cases differed from normal individuals in tha t  they showed a lesser 
increase or even a decrease in blood pressure in response to this drug. 
He did not, however, consider the atropine test more accurate than the 
ordinary diagnostic procedure and thus not of any practical use. I t  has 
also been reported that  schizophrenics usually give more variable blood 
pressure reactions to atropine than do normal subjects (DOCGLAS and 
Hock). 
Barbiturate sedation has been introduced by  S~AcAss (1954, 1956) 
as a tool for determination of the degree of tension and anxiety and for 
differentation between neurotic and psychotic types of depression. Other 
authors, however, have found this method of low objectivity (T~onPE and 
BARKEE; BRADLEY and JEAVO~S) and recently ACKNER (1959) - -  in 
spite of all efforts to make the procedure objective and reliable ~ did not 
find any significant correlation between test results and anxiety or tension. 
In view of the undoubted association between mental disorder and 
autonomic reactivity a search was made for drugs with adrenergic 
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blocking properties. Yohimbine hydrochloride (Fig. 1) among others 
was tried. Yohimbine in fairly high doses in animals exerts adrenolytie 
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(RAYMOND-HAMleT ; BA~u  ; YONKMAN et al. ; BOVET and BOVET-I~ITTI ; 
NICK~SON). The central nervous system actions are reported to be 
less prominent than those of the ergot alkaloids and benzodioxanes. 
No clinical experiences with yohimbine have been reported, and GOOD- 
MAN and GILMAN state that the drug has no proven therapeutic uses. 
We found this drug to have interesting autonomic and psychic effects 
which were correlated with the emotional reactivity of the subjects used 
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(I-IoL~z~G and GERs~os); and decided that  yohimbine warranted 
more detailed studies to evaluate further its usefulness as a clinical test 
drug and to investigate its mode of action. 
Materials and Methods 
A total of 60 cases was studied. Ten cases were used for experiments 
on modification of epinephrine reaction, seven of which also were used 
in studies of the preventative effects of sedatives. Three separate groups, 
of 15 schizophrenic patients, 9 normal volunteers, and 20 mental hospital 
patients with mixed diagnoses, were used in studies of the relation of 
yohimbine effects to emotional reactivity. Six further patients were 
given repeated doses of yohimbine for a study of its psychic effects. 
I t  is considered essential for effective rating that  a wide spectrum 
of patient material be studied, and that  the observations be carried out 
in a stable ward environment for at least three weeks. 
For the injection of autonomic drugs we adopted throughout the 
intravenous route at a constant dose rate. Before each experiment, a 
heparinized intravenous cannula was inserted and fixed on the arm. 
Through a rubber membrane on the cannula, injection could later be 
made as many times as needed without any pain or delay for puncture. 
The dose of yohimbine was 0.5 mg/kg, given at an even rate over 
a period of five minutes. Immediately before the injection a five minute 
baseline recording was done, and after the injection the effects were 
observed for at  least 15 minutes. During this whole procedure the EKG 
was recorded continuously and blood pressure taken by auscultation 
every 30 seconds. In some cases respiration and skin temperature were 
also recorded and the observation time extended over one hour (see 
section on direct autonomic effects). The autonomic effects of prepara- 
tory procedures (needle insertion and saline injection) were also recorded 
in connection with the studies of the relationship between yohimbine 
effects and emotional reactivity. 
Emotional reactivity was rated individually by seven skilled raters, 
using a scale with eight points. 






Very little sign of any reactions (more or less stuporous) 
Definitely (pathologically) sub-reactive 
Somewhat sub-reactive (the lowest a healthy person could possibly go 
many mentally ill people should also fall into this group) 
Normally reactive (without obvious signs of nervousness) 
Somewhat over-reactive (a little nervous) 
Rather over-reactive (quite nervous but not to a definitely pathological degree) 
Definitely over-reactive (shows abnormal degree of fear and anxiety) 
Strongly over-reactive (which means that the patient is among the most tense 
and anxious cases that can be managed in experiments) 
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The raters were instructed to note especially the reactions of anxiety 
or fear seen in the subjects during a two-month period of observation. 
Also the subjects were rank-ordered in the same respect, and the mean 
ranking list was used for a rank-order correlation (K~DALL) with the 
autonomic effects of yohimbine. The individual raters were found to 
be in good agreement, as K~DALL's  coefficient of concordance was 
.827 (P  < .00l ) .  
Results 
l)ireet autonomic effects. The initial response to the injection of 
yohimbine was facial flushing and an increase in heart  rate. FoUo~-ng 
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Fig. 2. The effect in  one case of prepa- 
ra to ry  procedures (N needle iasortion, 
S saline injection) and infusion of yo- 
himbine 0.5mg/kg (u  on systolic 
blood pressure mm t tg  (upper curve), 
hear t  rate  beats/min (middle curve) 
and respiratoryrate/min.  (lower curve) 
this, perspiration, salivation, lachryma- 
tion, and pupillary dilation were obser- 
ved, concomitant with a rise in blood 
pressure. In  the more markedly affected 
cases, nausea and sometimes urgency of 
micturit ion and defecation occurred. 
Erection was observed in 10--20% of 
the cases, apparent ly unrelated to other 
signs and symptoms.  
In  all our subjects the max imum 
h e a r t  rate increase ranged from 4 to 
48 beats per minute. The peak generally 
was reached during or immediately after 
the period of yohimbine injection, while 
return to baseline varied from 3 to over 
55 minutes. Those cases tha t  exhibited 
a less marked rise in heart  rate usually 
showed a secondary drop below baseline. 
Systolic blood pressure rose by  
2--93 ram. I-Ig., and this occurred more 
slowly than  the heart  rate response. The 
maxinum increase occurred 5--20 minutes 
after the injection, and the increase 
frequently lasted longer than  55 minutes 
(Fig. 2). Diastolic pressure generally 
showed a more moderate rise. 
The respiratory rate and volume usually increased a little. Hand  tem- 
perature generally fell, in most cases followed by  a secondary rise. Other 
autonomic signs essentially paralleled the degree of heart  rate change. 
Modification of epinephrine reaction. In  a group of 10 cases, con- 
sisting of five schizophrenics, two sociopaths, two alcoholics and one 
syphilitic chronic brain syndrome, epinephrine tests were performed 
Table 2 
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H e a r t  ra te  
Bea t s  per  m i n u t e  
Blood p ressu re  
Systol ic  m m  H g  




Epi.- I Differenoe 
91.1 + 3.7 




Epi- ] Difference 
108.0 -~ 23.7 
163.5 -~ 17.3 
15 minutes before and 15 minutes after yohimbine administration. The 
epinephrine dose was 0.20 y/kg/min given intravenously over a period 
of three minutes. 
As is seen from Table 2 epinephrine produced a significantly greater 
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The effect on systolic blood pressure ram ttg (upper curve) and heart rate beats/min. (lower 
of epinephrine infusion (Epi), before and after yohimbine infusion, l~or dosage, see text 
20 beats/minute more (range -~ 6 to + 38). This difference was signifi- 
cant at the 0.1% level. While in two cases the heart rate had decreased 
before, it now increased in all ten cases from epinephrine. 
The blood pressure after yohimbine was elevated to a higher level 
than before. The increase obtained with epinephrine now was less 
marked, an average 13.4 mm Hg less (range -- 51 to -~ 6). This diffe- 
rence was significant at the 5% level only. The actual blood pressure 
obtained with epinephrine was generally s t  least as high as before, 
except in two cases where the increase before yohimbine was unusually 
high (over 200 mm ttg). In  these cases the blood pressure obtained 
after yohimbine was within a more normal range. See Fig. 3. 
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A further observation was that  certain of the effects usually obtained 
with yohimbine, such as tremor, flushing and restlessness, became more 
marked when epinephrine was superimposed. 
Effect of sedatives on the autonomic changes. Seven of the 10 sub- 
jects of the above group were given amobarbital sodium 6.25 mg/kg 
intravenously prior to the administration of yohimbine. The sodium 
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Fig. 4. The effect of yohimbine infusion on systolic 
blood pressure mm Hg (the three upper curves) 
and heart rate beats/rain. (lower curves) without 
premedieation (0), after i . v .  injection of amo- 
barbital sodium (.Am) and after l~o 5--0690 
(Ro). For dosage see text 
the whole test period. Following 
the amytal, blood pressure was 
lowered and heart  rate was 
somewhat accelerated. Yohim- 
bine given at this point did 
not markedly change heart  rate;  
there was a mean decrease of 
1.6 beats/min, as compared to 
an increase of 11.8 beats/rain. 
when no sodium amytal had 
been given (difference signifi- 
cant at the 1% level). Blood 
pressure increased by 9.9ram 
Hg from yohimbine as com- 
pared to 16.6ram t tg  when 
no sodium amytal had b e e n  
given. Thus the sodium amytal  
abolished the heart  rate increase 
but  only reduced the blood pres- 
sure increase by 40% (P < .0 5 ) .  
See Fig. 4. In  no case so treated 
did the yohimbine produce any other visible autonomic changes such 
as perspiration, flushing, or change in respiration. 
Ro 5--0690 (7-chloro-2-methylamine-5-phenyl-3It-l,4-benzodiaze- 
pine 4-oxide hydrochloride 1) 1.5 mg./kg, given by  slow intravenous 
injection to the same seven individuals 15--20 minutes before the 
yohimbine ~est put only one of the subjects to sleep and made the 
others slightly drowsy. This level of depression was considerably less than 
seen with amobarbital; they could rationally respond to questions but  
with definite slurring of speech. Both heart  rate and blood pressure were 
somewhat lowered by this drug. Yohimbine gave a heart rate rise of 
6.7 beats/min, and a blood pressure rise of 15.8 mm ttg, which means a 
reduction by 43 % ( P <  .20) and 5% (not statistically significant) respec- 
tively, compared with the response to yohimbine alone. The other visible 
autonomic changes were reduced but  not to the same extent  as with 
amobarbital. 
i This preparation (Librium) was provided by Hoffmann La Roche Co. 
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Effect of medication with imipramine. Seven subjects (four schizo- 
phrenics, one alcoholic and two sociopaths) were studied to determine 
the effects of imipramine medication on the response to yohimbine. The 
imipramine was star ted after the first yohimbine test. The subjects 
were given a daily oral dosage of approximately  3 mg/kg body weight 
divided in three doses daily for three weeks, after which the second 
yohimbine test  was carried out. 
The average heart  rate rise produced by  yohimbine before imi- 
pramine was from 72 to 89 (difference @ 17) beats/rain. The baseline 
heart  rate was increased while on imipramine medication to an average 
of 96 beats/rain, and there was a further rise after yohimbine injection 
to 125 beats/rain. (difference +29) .  
The blood pressure increased from an average of 116 to 130 (difference 
+ 14) m m  t tg  from yohimbine alone, and after imipramine medication 
the increase was from 119 to 167 (difference ~-48) m m  ttg. Concomitant 
with this very marked and statistically significant increase in the yohim- 
bine effects brought about  by  the imipramine, there was also a poten- 
tiation of the other autonomic effects. There was a significant increase 
in the degree of flusMng, perspiration, tremor, and nausea above tha t  
induced by  yohimbine alone. 
Relation of autonomic changes to emotional reactivity. By obser- 
vation of the patients during the yohimbine test  it became evident tha t  
the overall degree of effect of the drug had a connection with the pre- 
existing emotional react ivi ty of the individual. A statistical correlation 
was shown to exist between the heart  rate change obtained with yohim- 
bine and the rated level of emotional reactivit:r On the other hand, 
no such correlation existed between the degree of blood pressure change 
and emotional reactivity.  
In  the first group, consisting of 15 schizophrenic patients, the cor- 
relation between heart  rate increase from yohimbine and emotional 
react ivi ty was .739 ( P <  .01). In  the second group, consisting of nine 
normal volunteers, findings were very similar, and the correlation was 
.925 ( P <  .01). In  the third group, consisting of 20 mental  hospital 
patients with varying diagnoses, again a correlation could be shown to 
exist, r 8 = .605 ( P <  .01). I t  could thus be safely stated tha t  the heart  
rate increase obtained from yohimbine injection had a definite relation- 
ship to the basic emotional reactivity. 
In  none of these three populations did the degree of blood pressure 
increase have any  significant correlation to emotional reactivity, r 8 = 
--.293, .160, and .086 respectively. In  the first group there was a 
correlation between the duration of the blood pressure increase and the 
emotional reactivity, r~ = -- .526 ( P <  .05). No such correlation existed 
in the latter two populations. 
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In the first as well as in the second group the baseline heart rate 
(as measured in the experimental situation) before the test correlated 
equally well with emotional reactivity, rs~-. 732 and 892 respectively 
(P< .01). In the third group the correlation was insignificant (.018) 
probably because these were patients that  had become familiar with the 
various laboratory procedures. Only in the first sample did a signi- 
f icant  correlation exist between baseline blood pressure and emotional 
reactivity, r s :  .746 ( P <  .01), while in the latter two the correlations 
were as low as .075 and --.194. 
The effect on heart  rate of preparatory procedures (insertion of an 
intravenous needle, injection of normal saline) correlated significantly 
with emotional reactivity in the first sample, r~----.610 ( P <  .05), while 
the correlations in the second (r s ----.579) and in the third (.377) were 
not significant. There was a significant correlation between the rise in 
heart  rate from the preparatory procedures and that  from yohimbine 
injection, r s ----.753 ( P <  .01) in the first group, and in the second r s :  
.667 ( P <  .05). In  the third the correlation (.338) was not significant. 
Only in this last group was there a very  significant correlation between 
emotional reactivity and the blood pressure effect of the preparatory 
procedures, r s = .697 (P < .001). In the first two groups the correlations 
were not significant. 
The relationship found between emotional reactivity and the effect 
of the drug on heart  rate was evidently fairly independent of diagnostic 
categories. I t  existed in the first schizophrenic group as well as in the 
normal volunteers. I t  also existed in the third group, consisting of 
both psychotic and non-psychotic mental hospital patients. When 
this latter group is broken up into one part consisting of 12 schizophrenic 
patients and one part consisting of eight non-schizophrenic patients 
(psychopathic and alcoholic cases and one case of syphilitic brain 
damage), the correlation within each of the parts is somewhat higher 
than for the total group (.729 in the schizophrenic group and .792 in the 
non-schizophrenic group). When the heart  rate increase from yohimhine 
in the 12 schizophrenics is compared to the increase in the eight non- 
schizophrenics, there is no significant difference. The range of heart 
rate change (mean over a 5 minute period) in the schizophrenic group 
was -- 1.0 to 3" 22.4 (mean 3-10.2), and in the non-schizophrenic group 
--.2 to 3-27.2 (mean 3,10.0) beats/min. This lack of difference is 
apparently due to the fact that  the schizophrenic patients showed all 
degrees of emotional reactivity, from strongly over-reactive to very 
unreactive states (score .7--6.1, mean 2.40), while the non-schizophrenic 
cases were scattered in a similar way, only within a somewhat narrower 
range (score 1.3 4.8, mean 3.25). The latter material of 20 cases was 
checked for possible correlations between drug effect on the  one hand 
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and age, t ime of s tay in the hospital, and body weight on the other hand. 
None of these correlations was significant even on the 10 % level. 
To date only one depressive has had s yohimbine test, a 48 year 
old man who has had two manic episodes on previous occasions and this 
t ime was admit ted  with endogenous depression. He was almost mute, 
showed signs of great fear and anxiety, and had classical delusions of a 
melancholic type. This ease showed the most marked heart  rate and 
blood pressure changes tha t  we have seen. The max imum heart  rate 
was 136 beats/rain, and max imum blood pressure 208 mm I~g. I t  took 
more than one hour before these changes had subsided. Also salivation, 
flushing, sweating, and laehrymation were of severe degree. Erection 
was also observed. 
Psychic 0fleets. Concomitant with the autonomic response to 
yohimbine, psychic changes were also observed, simulating an anxiety 
state. The subjects displayed a tense and anxious facial expression. 
They became restless, irritable, tremulous, and feelings of impatience 
and unrest were often experienced. In  the few eases where this state 
was very marked it usually coincided with feelings of nausea. The most  
affected subjects showed a marked reluctance toward repeating the 
yohimbine test. Apparent ly  the anxiety and fear induced by  the drug 
remained dear ly  in the subjects'  mind, which is in keeping with the 
observation tha t  the drug did not cause confusion. 
Premedication with amobarbi tal  sodium (see above) completely 
abolished all subjective sensations indueed by  yohilnbine, and only 
slight restlessness was observed whilst the subjects were asleep. Re 
5--0690 also reduced feelings of anxiety and tension but not to the same 
degree as the amytal.  Medication with imipramine greatly increased 
the severity of the psychic changes induced by  yohimbine. The t remor 
and restlessness became so marked in several cases tha t  it amounted 
to an acute panic. This potentiation from imipramine was such tha t  
even in previously unreactive subjects the response induced by  yohim- 
bine produced definite tremor, restlessness, tension and anxiety. 
In  a group of five schizophrenic subjects yohimbine was given intra- 
muscularly three times per week in doses dependent on the degree of 
response produced in the individual patient  (range 20--40 rag. per dose). 
Usually the dosage was eventually increased, as a degree of tolerance 
appeared to occur, but max imum was kept  at  40 rag. Of these five 
subjects, two showed a minimal over-all response to the injections. 
One was a schizophrenic in a state of remission with some remaining 
apa thy  and lack of initiative. The other was an extremely withdrawn, 
anergio, unresponsive little man who did not speak spontaneously at 
all and would reply to questions in monosyllables. The only significant 
effect produced with yohimbine was restlessness, t remor and slight 
Psyehopharmacologia, Bd. 2 8 
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anxiety-type response in the latter case. However, they both became 
more active, alert, outgoing and generally more responsive. The first 
case was released from the hospital after termination of medication, 
but  this may have had no relation to the medication. The other patient 
did not maintain this change after cessation of yohimbine. 
The other cases also become more active and mobile, but  their 
behavior was more disturbed. One admitted to auditory hallucinations 
and sat about muttering. All three became grossly disturbed for a 
period of about one hour after each injection of yohimbine. They actively 
hallucinated, laughed and addressed their hallucinations loudly, and 
made fists and threatened imaginary people and objects. This acute 
response completely subsided in, the latter pa r t o f  the day and they were 
then more alert, active and responsive than usual and a little euphoric. 
These effects were no longer present the next  day. 
The one depressive case studied showed initially a classic picture 
of endogenous depressive psychosis. He was inactive, hypochondrial, 
self-deprecatory and nihilistic, His speech was very retarded, and at 
times he was almost mute. After about one week on treatment his de- 
pression became definitely less severe, sleep improved, conversation 
was freer, and he was less nihilistic. But  towards the end of the second 
week his condition was agair~ approximately the same as at the commen- 
cement of treatment.  He then progressively became worse, which neces- 
sitated discontinuance of yohimbine. At the end of the third week his 
condition was one of severe agitated depression with suicidal thoughts. 
E. S. T, was instituted, and significant improvement resulted but 
inadequate for release to be even considered. 
Discussion 
I t  should be pointed out that  the methodology employed in this 
study is in several respects different from that  used in most of the 
established autonomic drug tests. In  the procedures suggested by 
FUZ~KENSTEIN et al. (1950) and by ttOFFE~ and CALLBEC~ (1959b), 
epinephrine is given in a rapid intravenous injection, and methacholine 
and atropine have been given by  the intramuscular route, all drugs in 
fixed standard doses. These procedures do not control for variable 
absorption from the i. m. route, dosage is not corrected for body weight, 
and, finally, speed and rate of intravenous injection are not defined. 
Age is a further factor which has been shown to be  of importance (NEL- 
SON and GELLRO~Z~) butisusually not controlled. On thebasis of the find- 
ings with two different drugs, FU~XENSTEI~ classifies his cases into 
categories which seem rather arbitrarily constructed without regard for 
the fact tha t  the epinephrine per  se does not seem to contribute to the 
resulting correlations (FvNKENSTEIN et al, 1952). For correlation with 
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these categories such complex factors as clinical diagnosis and the out- 
come of E.C.T.  and other treatments have been chosen. More recent 
studies have questioned the reliability of these methods ( M ~ s ;  JANe,) 
and furthermore have failed to substantiate many of the original find- 
ings (SLo~NE et al.; LUNDE et al.; t { O r F ~  and C~LLB~CK 1959a; 
SATTEI~FIELD; OZTURK et al.; BRAUN and RETTEK; BI~ILL et al.). 
The experimental procedure adopted in this study is so designed as 
to control for the variables of body weight, absorption, and speed of 
administration. Possible correlations with age are checked. Also, we 
a t tempt  correlation only between the actual quantitative responses 
obtained and the rating of a single fairly well-defined clinical variable, 
viz. the overall emotional reactivity. In individual eases observer error 
may introduce an inaccuracy in rating. Over a series of 60 cases, however , 
these random variations should cancel and allow an accurate assessment. 
There are no signs of correlation between test results and diagnosis, 
and no a t tempt  is made at correlating test results with prognosis 
which is a still more complex factor. A direct comparison between our 
results and those of the FUNKE~ST~IN group is not possible. 
The effects produced by  yohimbine are both adrenergic and eholin- 
ergie in nature. Flushing, sweating, salivation, lachrymation, urgency 
and frequency of micturition and defecation can likewise be produced 
by intravenous metacholine and may be considered to be predominantly 
cholinergie effects; whereas mydriasis, blood pressure increase, and 
perhaps tremor and tachycardia may be considered to be adrenergic 
type responses. 
The usual psychic effect produced by yohimbine in our subjects was 
an anxiety-type state. Similar effects have been reported from injected 
epinephrine, and the utilization of such drug-induced psychic responses 
has been investigated by other workers (LI~DE~rA~N and FI~SI~GE~; 
FU~:~STEIX et al. 1950). The anxiety response from yohimbine is, 
however, much greater than with epinephrine. Similar type responses 
may  occur with other sympathomimetie amines (IvY and K~ASNO) and 
with the indole alkaloid ibogaine ( S c ~ I D E ~  and Sine). These effects 
of yohimbine are, therefore, certainly of central origin. 
The adrenolytic properties ascribed to yohimbine in the literature 
(RAYMOND-HAMET ; BARI%Y ; u et  al. ; BOVET and BOVET-NITTI ; 
NICKERSON; GOODMAN and GrL~AN) were not observed in our study. 
This is most likely due to the much larger dosages (minimum 2- -7 ,  
usually 15--30 mg/kg) employed in the animal studies compared to 
our dosage of 0.5 mg/kg. JAva (1941) using very low concentration 
of yohimbine showed that  it  sensitized the perfnsed rabbits' ear to 
epinephrine. A similar phenomenon was also observed in our s tudy 
S* 
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in tha t  both the heart rate effects, tremor and psychic actions of epi- 
nephrine were markedly potentiated by a previous yohimbine dose. 
The central nervous system depressants and stimulants studied 
inhibited and potentiated, respectively, both the autonomic and the 
psychic effects of yohimbinc. This supports the view that  the yohimbine 
effects are to a great extent centrally mediated (cf. ]3OVET and BOVET- 
I~ITmI). This applies to all the effects of yohimbine except the rise in 
blood pressure, which was only partially reduced by premedication 
with amytM. 
The degree of autonomic and psychic responsiveness to yohimbine 
was shown in three separate populations to be correlated with the basic 
emotional reactivity, irrespective of diagnostic category, of age and 
body weight. Of the autonomic measures, this responsiveness is re- 
flected most accurately in the heart rate but not to any significant 
degree in the blood pressure. This test procedure can, therefore, give an 
index of responsiveness of the centers of emotional and autonomic 
reactivity in the thalamo-hypothalamic area. 
Yohimbine was also found to activate the more or less latent psycho. 
tic process in some of our schizophrenic subjects. There was an increase 
in general reactivity, active hallucinations, expression of delusions and 
demonstrations of disturbance in behavior. Two other indolc alkMoids, 
ibogMne and harmine, have been reported to have psychotomimetic 
effects with the production of excitement, inebriation states, mental 
confusion and hMlucinations. All three indole alkaloids show distinct 
centrM nervous system stimulant properties. As regards ibogMne, the 
findings indicate involvement of cholinergic mechanisms in the produc- 
tion of central stimulation (SCH~EIDE~ and SIGG). However, it  is diffi- 
cult to ascribe all the effects of yohimbine solely to the cholinergie 
effects, as adrenergic stimulation is obviously also involved. This may 
account for the differences seen with these two compounds although 
there is a basic similarity in their effect. 
Our findings indicate that  yohimbinc has marked autonomic and 
psychic effects which can be utilized for further studies. The Mmost 
specific anxiety-like response induced by yohimbine and its relationship 
with the basic level of emotional reactivity of the subjects is also of 
interest for further studies. Further,  in psychotic subjects, excluding 
very chronic deteriorated subjects, yohimbine seems to produce acti- 
vation of the psychotic picture. I t  would be of interest to study its 
effect on latent schizophrenic reactions. I t  is felt tha t  studies with 
this compound may be especially useful in studying the problem of 
reduced autonomic and emotional responsiveness in deterioration of 
diverse origins. I t  may be helpful in elucidating relationships between 




Yohimbine  in  a dose of 0 . 5 m g / k g  has  been g iven  to  51 male  
m e n t a l  hosp i t a l  sub jec t s  and  nine n o r m a l  volunteers .  
I t  has  p roduced  bo th  chol inergic  and  ad rene rg ic - type  au tonomic  
effects and  psychic  effects s imula t ing  an  a n x i e t y  s ta te .  The degree of 
bo th  these  responses  to yoh imbine  correlates  h igh ly  wi th  the  basic  
level  of emot iona l  r eac t iv i t y .  
Cent ra l  nervous  sys t em d e p r e s s a n t s , . a m o b a r b i t a l  and  Ro 5- -0690,  
r educed  the  degree of response to  yohimbine ,  whi ls t  the  CNS s t imu-  
lan t s  im ip ramine  and  ep inephr ine  p o t e n t i a t e d  the  yoh imbine  effect.  
u  in  the  dosage here employed  d id  no t  have  a n y  blocking 
effect aga ins t  in jec ted  epinephr ine .  
A c t i v a t i o n  of the  psychot ic  p ic ture  was p roduced  b y  yoh imbine  in 
some schizophrenic  cases. 
Yoh imbine  is a p romis ing  compound  for use as an  au tonomic  t es t  
drug.  
Aeknowledgements. The authors would like to thank Dr. L. H. B~cK for his 
invaluable assistance with the polygraphic studies and Mr. N. MATTSON for his 
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